Compare ARCO & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARCO | NBTX |
|---|---|---|
| Founded | 2007 | 2003 |
| Country | Uruguay | France |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2011 | 2018 |
| Metric | ARCO | NBTX |
|---|---|---|
| Price | $8.07 | $22.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | $11.23 | ★ $54.00 |
| AVG Volume (30 Days) | ★ 2.2M | 135.5K |
| Earning Date | 11-11-2026 | 09-24-2026 |
| Dividend Yield | ★ 3.47% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.75 | N/A |
| Revenue Next Year | $6.49 | $50.69 |
| P/E Ratio | $7.26 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.67 | $14.78 |
| 52 Week High | $9.75 | $57.14 |
| Indicator | ARCO | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 56.35 | 29.66 |
| Support Level | $8.03 | $19.99 |
| Resistance Level | $8.38 | $35.38 |
| Average True Range (ATR) | 0.27 | 1.57 |
| MACD | 0.08 | -0.37 |
| Stochastic Oscillator | 85.85 | 13.69 |
Arcos Dorados Holdings Inc operates McDonald's branded restaurants in various countries and territories in Latin America and the Caribbean. The Company manages its business as distinct geographic segments and its operations are divided into three geographic divisions, as follows: Brazil, the North Latin American division, or NOLAD, which is comprised of Costa Rica, Mexico, Panama, Puerto Rico, Martinique, Guadeloupe, French Guiana and the U.S. Virgin Islands of St. Croix and St. Thomas and the South Latin American division, or SLAD, which is comprised of Argentina, Chile, Ecuador, Peru, Uruguay, Colombia, Venezuela, Trinidad and Tobago, Aruba and Curacao. Its menu includes hamburgers, McNuggets, salad, sandwiches, French fries, and others. It generates maximum revenue from Brazil.
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.